Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models.
Begg LR, Orriols AM, Zannikou M, Yeh C, Vadlamani P, Kanojia D, Bolin R, Dunne SF, Balakrishnan S, Camarda R, Roth D, Zielinski-Mozny NA, Yau C, Vassilopoulos A, Huang TH, Kim KA, Horiuchi D. Begg LR, et al. Among authors: kanojia d. Commun Med (Lond). 2024 Feb 20;4(1):22. doi: 10.1038/s43856-024-00444-8. Commun Med (Lond). 2024. PMID: 38378783 Free PMC article.
Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.
Kunder R, Velyunskiy M, Dunne SF, Cho BK, Kanojia D, Begg L, Orriols AM, Fleming-Trujillo E, Vadlamani P, Vialichka A, Bolin R, Perrino JN, Roth D, Clutter MR, Zielinski-Mozny NA, Goo YA, Cristofanilli M, Mendillo ML, Vassilopoulos A, Horiuchi D. Kunder R, et al. Among authors: kanojia d. Cell Chem Biol. 2022 Mar 17;29(3):358-372.e5. doi: 10.1016/j.chembiol.2021.08.011. Epub 2021 Sep 14. Cell Chem Biol. 2022. PMID: 34525344 Free PMC article.
S100A8/A9 predicts triple-negative breast cancer response to PIM kinase and PD-1/PD-L1 inhibition.
Begg LR, Orriols AM, Zannikou M, Yeh C, Vadlamani P, Kanojia D, Bolin R, Dunne SF, Balakrishnan S, Camarda R, Roth D, Zielinski-Mozny NA, Yau C, Vassilopoulos A, Huang TH, Kim KA, Horiuchi D. Begg LR, et al. Among authors: kanojia d. bioRxiv [Preprint]. 2023 Sep 23:2023.09.21.558870. doi: 10.1101/2023.09.21.558870. bioRxiv. 2023. PMID: 37790346 Free PMC article. Updated. Preprint.
Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
Zhang P, Miska J, Lee-Chang C, Rashidi A, Panek WK, An S, Zannikou M, Lopez-Rosas A, Han Y, Xiao T, Pituch KC, Kanojia D, Balyasnikova IV, Lesniak MS. Zhang P, et al. Among authors: kanojia d. Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23714-23723. doi: 10.1073/pnas.1906346116. Epub 2019 Nov 11. Proc Natl Acad Sci U S A. 2019. PMID: 31712430 Free PMC article.
Low-level whole-brain radiation enhances theranostic potential of single-domain antibody fragments for human epidermal growth factor receptor type 2 (HER2)-positive brain metastases.
Procissi D, Jannetti SA, Zannikou M, Zhou Z, McDougald D, Kanojia D, Zhang H, Burdett K, Vaidyanathan G, Zalutsky MR, Balyasnikova IV. Procissi D, et al. Among authors: kanojia d. Neurooncol Adv. 2022 Aug 23;4(1):vdac135. doi: 10.1093/noajnl/vdac135. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36128586 Free PMC article.
Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade.
Dmello C, Zhao J, Chen L, Gould A, Castro B, Arrieta VA, Zhang DY, Kim KS, Kanojia D, Zhang P, Miska J, Yeeravalli R, Habashy K, Saganty R, Kang SJ, Fares J, Liu C, Dunn G, Bartom E, Schipma MJ, Hsu PD, Alghamri MS, Lesniak MS, Heimberger AB, Rabadan R, Lee-Chang C, Sonabend AM. Dmello C, et al. Among authors: kanojia d. Nat Commun. 2023 Mar 22;14(1):1566. doi: 10.1038/s41467-023-36878-2. Nat Commun. 2023. PMID: 36949040 Free PMC article.
Current state of clinical trials in breast cancer brain metastases.
Fares J, Kanojia D, Cordero A, Rashidi A, Miska J, Schwartz CW, Savchuk S, Ahmed AU, Balyasnikova IV, Cristofanilli M, Gradishar WJ, Lesniak MS. Fares J, et al. Among authors: kanojia d. Neurooncol Pract. 2019 Sep;6(5):392-401. doi: 10.1093/nop/npz003. Epub 2019 Feb 11. Neurooncol Pract. 2019. PMID: 31555454 Free PMC article.
Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma.
Dmello C, Sonabend A, Arrieta VA, Zhang DY, Kanojia D, Chen L, Gould A, Zhang J, Kang SJ, Winter J, Horbinski C, Amidei C, Győrffy B, Cordero A, Chang CL, Castro B, Hsu P, Ahmed AU, Lesniak MS, Stupp R, Sonabend AM. Dmello C, et al. Among authors: kanojia d. Clin Cancer Res. 2022 Jul 15;28(14):3156-3169. doi: 10.1158/1078-0432.CCR-21-2563. Clin Cancer Res. 2022. PMID: 35552677 Free PMC article.
79 results